Health Technology · Pharmaceuticals: Major · NSE: CORONA · data 2026-10-09
Corona Remedies Limited
Health check: Strong (7.5/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹2,024
Market cap
₹12,156 cr
P/E
62.2
P/B
—
ROE
27.4%
ROCE
32.4%
Debt / equity
0.22
Dividend yield
0.50%
1-year return
37.7%
52-week high
₹2,292.4
52-week low
₹1,336.6
Operating margin
18.6%
Growth
| Revenue (last 12 months) | ₹1,479 cr |
| Net profit (last 12 months) | ₹199 cr |
| Sales growth, 3 years (yearly) | 16.6% |
| Profit growth, 3 years (yearly) | 29.7% |
Chart patterns
- Double top — forming (key level ₹2,020.2)
Similar companies
AstraZeneca Pharma India Limited (ASTRAZEN) · Indegene Limited (INDGN) · Marksans Pharma Limited (MARKSANS) · Anupam Rasayan India Ltd. (ANURAS) · Viyash Scientific Limited (VIYASH)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open CORONA in NSE Scanner →